Navigation Links
Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
Date:1/12/2009

ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a licensing agreement with Abbott, which marks the achievement of significant milestones within their on-going Research and Option Agreement for development and commercialization of Rubicon MethylPlex(TM) methylation detection technology for the diagnosis and prognosis of cancer.

Under the terms of the agreement Abbott receives a non-exclusive license to MethylPlex for in vitro molecular diagnostics to detect the presence or risk of prostate, bladder and colon cancer for screening and non-screening indications. Abbott also obtains a non-exclusive license for non-screening applications with other diseases and options to colon cancer biomarkers developed in collaboration with Rubicon.

"This license is a significant validation of the MethylPlex technology as an effective, simple, automatable method for detecting cancer using DNA methylation in patient plasma," said James Koziarz, Acting President and CEO of Rubicon. Mr. Koziarz went on to say, "The collaboration between Rubicon and Abbott has been very productive with both parties making significant contributions towards development and commercialization of IVD products that employ MethylPlex biomarkers and assays. We look forward to continuing our joint efforts under our collaboration and developing leading edge products."

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performance of analytical platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbiased amplification and standardization of total DNA, total RNA, and methylated DNA. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensitivity, specificity, and reproducibility of conventional instrumentation in research and diagnostic applications, including analysis of single cells, formalin-fixed tissue and plasma. Rubicon sells GenomePlex and TransPlex services to the research market, as well as licenses and kits to the clinical markets, including pre-implantation and prenatal testing, and diagnostic manufacturing. GenomePlex and TransPlex kits are sold to the research-only market by Sigma-Aldrich. In addition, Rubicon partners with diagnostic companies using MethylPlex to discover and validate novel DNA methylation biomarkers, and to co-develop cancer diagnostic tests. For more information and to contact Rubicon, please visit www.rubicongenomics.com.


'/>"/>
SOURCE Rubicon Genomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
2. Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. UC San Diego to lead nationwide program in pharmacogenomics
5. NeoGenomics to Present at the Noble Financial Equity Conference
6. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
7. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
8. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
9. AutoGenomics Receives a Key European Patent for HPV Detection
10. Genomics of Cardiovascular Disease: Current Clinical Applications
11. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Donor ... and Nevada and LABS, Inc., announced the future opening of a CLIA certified ... and serology testing used to determine the suitability of potential organ and ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, ... to accept new patients in need of skilled pediatric dentistry in Rock ... Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a ...
(Date:3/22/2017)... Milford, PA (PRWEB) , ... March 22, 2017 , ... ... producers, according to a US Department of Agriculture report. While excess dairy can ... sensitivity play a role. Lactose sensitivity is the inability to properly digest lactose, a ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... financial consultations to families and business owners in the greater Hampton Roads area, ... American Cancer Society Relay For Life event. , Each year, hundreds of people ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22. März 2017   ... und weltweit tätige Anbieter von Produkten und ... den Erwerb von EPL Archives Inc. bekannt, ... der Kunden im kompletten Zyklus regulierter Forschung, ... von Proben, Speicherung von Dokumenten und Zusatzdienstleistungen ...
(Date:3/22/2017)... 2017 TapImmune, Inc. (NASDAQ: ... development of innovative peptide and gene-based immunotherapeutics for ... announced that it will participate in two upcoming ... Glynn Wilson , Chairman and CEO of TapImmune, ... clinical pipeline and partnering opportunities for its proprietary ...
(Date:3/22/2017)... 22, 2017 A new independent study ... the proven ultraviolet-C (UV-C) disinfection solution of choice ... Published in the March issue ... , the peer-reviewed study of UV-C disinfection systems ... General Hospital and Rochester General Hospital. According to ...
Breaking Medicine Technology: